VetMedGuide

Vet Med Guide

Diagnostics2026-05-14 · 11 min read

SDMA vs Creatinine in Cats: Early CKD Detection, Muscle Mass, and False Reassurance

How SDMA and creatinine compare for detecting feline chronic kidney disease, why muscle mass makes creatinine unreliable in thin seniors, and what to do when the two markers disagree.

Ran Chen
Ran Chen
Founder, VetMedGuide. Life-sciences operator and 10× global market-access lead.
Published

When a veterinarian screens a cat for kidney disease, the two most common blood markers on the panel are creatinine and SDMA (symmetric dimethylarginine). Both are surrogate markers for glomerular filtration rate (GFR) — they tell you how well the kidneys are filtering, but they do not tell you why filtration has declined, and neither one alone gives a complete picture.

The practical question that matters to cat owners is: does my cat have kidney disease, how early can we know, and which number should I trust? The answer is that both numbers matter, they sometimes disagree, and understanding why they disagree — particularly the role of muscle mass — is the most important part of interpreting kidney screening in cats.

Quick answer

  • Creatinine is a breakdown product of muscle metabolism, filtered by the kidneys. It is the traditional marker used for decades. Its main limitation: it is influenced by muscle mass. A thin, sarcopenic senior cat produces less creatinine, so blood creatinine can look normal even when kidney function is already declining. This is the "false reassurance" problem.
  • SDMA is a methylated amino acid released by all nucleated cells and cleared almost exclusively by the kidneys. It is less affected by muscle mass. Research shows SDMA may increase an average of 17 months before creatinine in cats that go on to develop CKD.
  • IRIS (International Renal Interest Society) recommends using both markers together for staging. When they disagree, IRIS recommends staging based on the higher of the two markers.
  • Neither marker is perfect. A 2026 systematic review found significant remaining uncertainty about SDMA's diagnostic accuracy, and emphasized that SDMA should be interpreted alongside creatinine, urinalysis, and the clinical picture — not as a standalone test.

What each marker measures

Creatinine

Creatinine is produced at a relatively constant rate from muscle creatine phosphate breakdown. It is freely filtered by the glomerulus with minimal tubular reabsorption or secretion in cats. Blood creatinine concentration reflects the balance between production (which depends on muscle mass) and excretion (which depends on GFR).

The upper limit of the reference interval for serum creatinine in cats is typically around 1.6–2.3 mg/dL depending on the laboratory. IRIS Stage 2 CKD begins at creatinine ≥ 1.6 mg/dL.

Limitations:

  • Muscle mass dependence. This is the central problem. A cat that has lost significant lean muscle mass — common in senior cats, cats with hyperthyroidism, and cats already in early CKD — produces less creatinine. The result is a blood creatinine concentration that underestimates the severity of renal dysfunction. The kidneys may be filtering poorly, but because there is less creatinine being produced, the blood level appears deceptively normal.
  • Late rise. Creatinine typically does not rise above the reference interval until approximately 75% of kidney function has been lost. A cat can be in early CKD with a "normal" creatinine.
  • Non-renal influences. Diet (protein intake), hydration status, and sampling conditions can all affect creatinine.

SDMA

SDMA is a methylated derivative of the amino acid arginine, released by all nucleated cells as a byproduct of protein turnover. It is cleared predominantly by renal filtration, with minimal extra-renal elimination.

The upper limit of the reference interval for SDMA in both dogs and cats is 14 μg/dL. IRIS considers persistently elevated SDMA (>14 μg/dL) to be consistent with a diagnosis of CKD even in the absence of other findings.

Advantages:

  • Less affected by muscle mass. Because SDMA is produced by all nucleated cells (not just muscle), it does not decline proportionally when a cat loses muscle. A thin cat with declining kidney function will still show a rising SDMA.
  • Earlier detection. A landmark study (Hall et al., 2014) found that SDMA increased above the reference interval a median of 17 months before creatinine in cats with naturally occurring CKD. SDMA may detect a GFR reduction of approximately 25%, compared to the ~75% reduction typically needed to push creatinine above the reference interval.
  • Higher sensitivity for early disease. This is particularly valuable in senior cats — the population most at risk for CKD and most likely to have low muscle mass.

Limitations:

  • Not perfectly specific. SDMA can be influenced by non-renal factors including thyroid status (hyperthyroidism may lower SDMA, similar to its effect on creatinine), certain neoplastic conditions, and individual biological variation.
  • False positives are a concern. A 2026 systematic review published in Veterinary Record (Scobie et al.) evaluated the diagnostic accuracy of SDMA and found significant uncertainty, noting that studies had high risk of bias and that low specificity in some analyses raises concerns about false positives, particularly in screening populations.
  • Single values can be misleading. A mildly elevated SDMA in an otherwise healthy cat should be confirmed with repeat testing before triggering a full CKD workup. IDEXX data show that for cats with a first SDMA within the reference interval (≤14 μg/dL), a subsequent increase to 15–19 μg/dL was only persistent in a subset of cases.
  • Cost and availability. SDMA testing is widely available through IDEXX and other reference laboratories but may not be included in all standard panels and may carry an additional charge.

IRIS staging: how both markers fit together

IRIS CKD staging uses both creatinine and SDMA:

Stage Creatinine (mg/dL) SDMA (μg/dL)
1 < 1.6 < 18 (but other evidence of CKD present)
2 1.6–2.8 18–25
3 2.9–5.0 26–38
4 > 5.0 > 38

Key staging rules from IRIS:

  • Stage only on stable, well-hydrated patients. Acute kidney injury, dehydration, and post-renal obstruction must be ruled out first.
  • Persistently elevated SDMA > 14 μg/dL may be used to diagnose early CKD (Stage 1) even when creatinine is normal.
  • When creatinine and SDMA stage differently (discrepant in about 17% of cats), IRIS recommends staging based on the higher of the two markers.
  • Cats with SDMA persistently > 18 μg/dL but creatinine < 1.6 mg/dL should be staged and treated as IRIS CKD Stage 2.
  • Cats with SDMA persistently > 25 μg/dL but creatinine in the Stage 2 range should be staged as Stage 3.

IRIS also sub-stages by proteinuria (UPC ratio) and blood pressure, because these are treatable risk factors that influence disease progression independently of creatinine or SDMA.

The false reassurance problem

Consider a 14-year-old cat presented for a senior wellness screen. The cat has lost weight over the past year — the owner attributes it to "getting old." Bloodwork shows:

  • Creatinine: 1.4 mg/dL (within the reference interval of 0.8–2.3 mg/dL)
  • SDMA: 19 μg/dL (above the 14 μg/dL reference interval)

If only creatinine were measured, this cat would appear to have normal kidney function. But the elevated SDMA, in the context of weight loss and age, suggests early CKD. The cat's low muscle mass is suppressing the creatinine, making kidney function appear better than it is.

This scenario is common. The Hall et al. (2014) study found that SDMA detected CKD an average of 17 months before creatinine in affected cats. Those 17 months matter because early intervention — primarily renal diet transition — has been shown to slow disease progression and improve survival. A 2026 study published in JAVMA found that cats consistently prescribed a renal diet across all early CKD stages were 41–46% less likely to progress to a more advanced stage and had a 30% reduction in all-cause mortality.

This is why running SDMA alongside creatinine in senior cats is not redundant — it fills a gap that creatinine alone leaves open.

When creatinine and SDMA disagree

Discrepancies occur in roughly 9% of dogs and 17% of cats. When they do:

  1. Consider muscle mass. If the cat is thin, underweight, or has documented muscle loss, SDMA is more likely to reflect true kidney function than creatinine. The creatinine may be falsely low due to reduced muscle mass.
  2. Recheck both values in 2–4 weeks. IRIS recommends confirming persistent elevation before staging or making treatment decisions. A single abnormal value is not enough.
  3. Stage by the higher marker. IRIS recommends using the stage indicated by whichever marker places the cat in the higher (more advanced) stage.
  4. Look at the full picture. Urine specific gravity (USG), UPC ratio, blood pressure, and imaging findings all contribute to staging and treatment decisions. Creatinine and SDMA are pieces of a larger diagnostic puzzle.

What a cat owner should ask their veterinarian

  • Is SDMA included in my cat's blood panel? Not all wellness panels include it by default. If your cat is 7 years or older, ask whether SDMA should be added.
  • What are both numbers — creatinine and SDMA? Do not accept a statement that "kidney values are normal" without knowing which values were checked and whether both markers were included.
  • Has my cat's muscle mass been assessed? A body condition score and muscle condition score should accompany bloodwork in senior cats. Low muscle mass makes creatinine less reliable.
  • If SDMA is elevated, what is the next step? The answer should include a recheck in 2–4 weeks to confirm persistence, a urinalysis (including USG and UPC ratio), and blood pressure measurement.
  • What is the stage, and what are the substages? IRIS staging includes proteinuria and hypertension substaging. These are treatable factors that affect prognosis.
  • Is a renal diet appropriate at this stage? The 2026 JAVMA study supports renal diet introduction in early CKD stages, not just advanced disease. Discuss timing with your veterinarian.
  • How often should we recheck? For early-stage CKD, rechecks every 3–6 months are typical. For more advanced stages, monitoring may be more frequent.

Limitations and honest caveats

SDMA is a better early-detection tool than creatinine in many cats, but it is not a perfect test:

  • The 2026 Veterinary Record systematic review concluded that "significant uncertainty remains regarding the diagnostic accuracy of SDMA" and that many published studies had high risk of bias. The authors emphasized that SDMA should not be used as a standalone diagnostic.
  • False positives — mildly elevated SDMA that does not persist on recheck — are a real clinical problem. They can cause owner anxiety and lead to unnecessary additional testing if not managed with repeat measurement before staging.
  • The benefit of detecting CKD earlier depends on whether the owner and veterinarian act on the result. A persistently elevated SDMA that triggers a renal diet transition and regular monitoring has clear value. An elevated SDMA that is not followed up provides no clinical benefit.
  • Some veterinarians in practice have noted that SDMA can create uncertainty for clients — a borderline value that resolves on recheck can erode trust in the diagnostic process. Clear communication about what a mildly elevated SDMA means (and does not mean) is essential.

Key points

  • Creatinine is influenced by muscle mass; thin senior cats can have falsely reassuring creatinine values. SDMA is less affected by muscle mass and can detect CKD earlier.
  • SDMA rose an average of 17 months before creatinine in cats that developed CKD. Early detection matters because renal diet and monitoring in early stages slow progression.
  • IRIS recommends using both markers together. When they disagree, stage by the higher marker and recheck in 2–4 weeks.
  • SDMA is not a perfect test. A 2026 systematic review found remaining uncertainty about its diagnostic accuracy, and false positives are a concern. Confirm any mildly elevated value with repeat testing.
  • Both markers are surrogate measures of GFR. Neither tells you why kidney function is declining. Urinalysis, blood pressure, and the full clinical picture remain essential.

Sources

Topics
Feline CKDClinical Pathology
Related Articles